logo
  

Safe Bulkers Q1 Profit Declines; Declares Dividend - Quick Facts

Safe Bulkers Inc. (SB), Wednesday said first-quarter net income available to common shareholders was $10.4 million or $0.13 per share, compared to $16.1 million or $0.21 per share in the comparable quarter last year.

Adjusted net income available to common shareholders for the latest first quarter was $8.6 million or $0.10 per share, down from $16.0 million or $0.21 per share in the prior year period. On average, 10 analysts polled by Thomson Reuters expected the company to earn $0.11 per share for the quarter. Analysts' estimates typically exclude special items.

Net revenues decreased 7 percent to $41.34 million from $44.23 million last year, while seven analysts expected revenues of $37.43 million.

Further, the Board of Directors of the company declared a cash dividend on the company's common stock of $0.06 per share payable on or about June 17, 2014 to shareholders of record at the close of trading of the company's common stock on June 10, 2014.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lincoln Park, New Jersey -based ConSup North America Inc. is recalling around 85,984 pounds of ready-to-eat or RTE sliced prosciutto ham product produced in Germany without the benefit of equivalent inspection, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and...

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT